论文部分内容阅读
目的:探讨前列地尔对支气管哮喘患者血清白介素-5(IL-5)、白介素-8(IL-8)和转化生长因子β1(TGF-β1)及肺功能指标第一秒用力呼气容积(FEV1)、第一秒用力呼气容积占预计值百分比(FEV1%pre)的影响。方法:选择2015年12月~2016年11月湖南师范大学第二附属医院呼吸内科确诊的支气管哮喘患者60例,分为2组即常规治疗组(A组)和前列地尔干预组(B组)各30例。A组采用常规治疗即控制性氧疗、抗感染及扩张气道治疗;B组则在A组的基础上加用前列地尔干乳剂10μg+0.9%氯化钠注射液100mL静滴,每日1次,连续治疗时间为1周。A组及B组均在治疗前第1天和治疗后第7天分别于清晨空腹取肘静脉血5mL,测定IL-5、IL-8和TGF-β1并进行比较,以比较两组患者临床疗效,即显效率。结果:A组及B组治疗前血清IL-5、IL-8及TGF-β1水平无明显差异;治疗后A、B两组各项检测指标较治疗前均有所改善,且B组血清IL-5、IL-8及TGF-β1水平与A组相比下降更明显,差异均有统计学意义;治疗后A组和B组肺功能亦均较治疗前有所改善,且B组明显优于A组。结论:前列地尔能够降低哮喘患者体内IL-5、IL-8和TGF-β1水平,抑制气道炎症反应、缓解气道痉挛、增加通气,改善患者肺功能。
Objective: To investigate the effects of alprostadil on serum interleukin-5 (IL-5), interleukin-8 (IL-8) and transforming growth factor-β1 (TGF-β1) and pulmonary expulsive volume in patients with bronchial asthma FEV1), forced expiratory volume in the first second as a percentage of expected value (FEV1% pre). Methods: Sixty patients with bronchial asthma diagnosed in Department of Respiratory Medicine, Second Affiliated Hospital of Hunan Normal University from December 2015 to November 2016 were selected and divided into two groups: conventional treatment group (A group) and alprostadil treatment group (B group) ) 30 cases in each. A group of conventional treatment that is controlled oxygen therapy, anti-infection and expansion of airway therapy; B group is based on the A group plus alprostadil dry emulsion 10μg + 0.9% sodium chloride injection 100mL intravenous infusion daily 1 times, continuous treatment time of 1 week. In group A and group B, 5 mL of elbow venous blood was collected on the first day before treatment and on the seventh day after treatment respectively. The levels of IL-5, IL-8 and TGF-β1 were measured and compared in the two groups Efficacy, that is significant efficiency. Results: The serum levels of IL-5, IL-8 and TGF-β1 in group A and group B before treatment were not significantly different. After treatment, the detection indexes of group A and B were all improved compared with that before treatment, and the serum IL The levels of IL-8, IL-8, IL-8 and TGF-β1 in group A and B were significantly lower than those in group A, but the difference was statistically significant In Group A Conclusion: Alprostadil can reduce the levels of IL-5, IL-8 and TGF-β1 in asthmatic patients, inhibit airway inflammation, relieve airway spasm, increase ventilation and improve pulmonary function.